Abstract
Background: Since December 2019, there has been an increasing number of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world. As of March 2020, the World Health Organization declared a global pandemic.
Case Presentation: To our best knowledge, this is the first report of a patient with SARS-CoV-2 infection presenting with constrictive pericarditis, possibly from the COVID infection. She was presented after a week of fever, persistent dry cough, and diarrhea. She received a single dose of hydroxychloroquine 400 mg, Oseltamivir 75 mg every 12 hours, lopinavir/ritonavir (Kaletra) 400/100 mg every 12 hours, and levofloxacin 750 mg daily. After 24 hours, she was immediately transferred to the Intensive Care Unit (ICU) because of dyspnea and progressive respiratory failure with a drop of the O2 saturation to 70%.
Conclusion: After a week of progress, her respiratory condition deteriorated again. She was re-admitted to the ICU and she expired. She died due to constrictive pericarditis, most probably caused by SARS-CoV-2.
Keywords: COVID-19, SARS-CoV-2, pneumonia, ARDS, pericarditis, cardiac tamponade.
Graphical Abstract
Infectious Disorders - Drug Targets
Title:Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report
Volume: 21 Issue: 7
Author(s): SeyedAhmad SeyedAlinaghi, Maryam Ghadimi, Mehrnaz Asadi Gharabaghi and Fereshteh Ghiasvand*
Affiliation:
- Department of Infectious Diseases, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran,Iran
Keywords: COVID-19, SARS-CoV-2, pneumonia, ARDS, pericarditis, cardiac tamponade.
Abstract: Background: Since December 2019, there has been an increasing number of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world. As of March 2020, the World Health Organization declared a global pandemic.
Case Presentation: To our best knowledge, this is the first report of a patient with SARS-CoV-2 infection presenting with constrictive pericarditis, possibly from the COVID infection. She was presented after a week of fever, persistent dry cough, and diarrhea. She received a single dose of hydroxychloroquine 400 mg, Oseltamivir 75 mg every 12 hours, lopinavir/ritonavir (Kaletra) 400/100 mg every 12 hours, and levofloxacin 750 mg daily. After 24 hours, she was immediately transferred to the Intensive Care Unit (ICU) because of dyspnea and progressive respiratory failure with a drop of the O2 saturation to 70%.
Conclusion: After a week of progress, her respiratory condition deteriorated again. She was re-admitted to the ICU and she expired. She died due to constrictive pericarditis, most probably caused by SARS-CoV-2.
Export Options
About this article
Cite this article as:
SeyedAlinaghi SeyedAhmad , Ghadimi Maryam , Gharabaghi Asadi Mehrnaz and Ghiasvand Fereshteh*, Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report, Infectious Disorders - Drug Targets 2021; 21 (7) : e160921188928 . https://dx.doi.org/10.2174/1871526520666201209145001
DOI https://dx.doi.org/10.2174/1871526520666201209145001 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversing Anticoagulant Therapy
Current Drug Discovery Technologies Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets Applied Pathology for Interventions of Coronary Chronic Total Occlusion
Current Cardiology Reviews Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Mitral Balloon Valvuloplasty: State-of-the-Art Paper
Current Cardiology Reviews Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Imaging of Chest and Abdominal Trauma in Children
Current Pediatric Reviews Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Chylothorax
Current Respiratory Medicine Reviews Antithrombotic Therapy for Transcatheter Valvular Interventions: A Revisit
Current Vascular Pharmacology Descending Necrotizing Mediastinitis: Current Strategies for Diagnosis and Treatment
Current Respiratory Medicine Reviews Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Transseptal Access to the Left Atrium: Tips and Tricks to Keep it Safe Derived from Single Operator Experience and Review of the Literature
Current Cardiology Reviews Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews